A hidden atrial dysfunction may raise stroke risk in people with transthyretin amyloid cardiomyopathy (ATTR-CM); however, a non-invasive assessment tool may help identify those at increased risk, according to a preliminary study to be presented at the American Heart Association’s Scientific Sessions 2025. The disease is a progressive condition that stiffens the heart muscle and may raise the risk of stroke , even when the heart rhythm appears normal.

The meeting, Nov. 7-10, in New Orleans, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a potentially fatal disease that has historically been considered rare. However, it is difficult to

See Full Page